Because the increasing prevalence of atrial fibrillation imposes significant financial and clinical burdens, efficient healthcare delivery is required to improve outcomes and reduce associated costs.
For patients who use biologic treatments for rheumatoid arthritis, specialty pharmacy care yields higher medication adherence and lower medical costs than retail pharmacy care.
For US payers, pegfilgrastim is a less-expensive choice than daily filgrastim for reducing the risk of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
Pharmacists struggling to reconcile their duty to dispense with legal obligations to prevent drug diversion must exercise judgment when determining whether a prescription is suspect or legitimate.Â
In a retrospective analysis of the Optum database, overactive bladder patients treated with mirabegron bladder patients persisted longer with treatment than patients treated with tolterodine, and had reduced resource utilization and costs.
Consider patients' disease states, medication regimens, and other regularly used nonprescription drugs.
Lisocabtagene maraleucel chimeric antigen receptor T-cell therapy significantly enhances treatment of relapsed/refractory B-cell malignancies, offering high response rates and durable remissions.
To maximize this challenging experience, pharmacy students should be eager to learn and inquisitive.
Health care policy decisions based on sound data and research are essential for addressing the challenges.
Although specialty therapies have the potential to help people live healthier lives, their cost and complexity can create distinct challenges.
Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.
With so many radical developments in medicine and technology unfolding at once, the role and potential of the pharmacy as we know it is evolving at breakneck speed.
Lacy La Fever, PharmD, MS, discussed outcomes associated with different carboplatin AUC dosing strategies.
Jonas Congelli, RPh, discusses how limited distribution networks and medically integrated pharmacies can improve access, continuity, and quality of oncology care—particularly in underserved areas—while addressing systemic barriers posed by traditional distribution models and pharmacy benefit managers.
This review discusses the prevalence, mechanisms of development, and evolving treatment landscape in chronic lymphocytic leukemia.
Non–FDA-approved medications may be accessed for patient care via 3 alternative pathways: expanded access, the Right to Try Act, and off-label use, which are reviewed in this article.
Specialty pharmacies can leverage advanced analytics, AI, and comprehensive data insights to create targeted clinical programs.
There is a real opportunity for technology to alleviate some of the administrative burdens pharmacists face so that they have more time to focus on patient care.
Interested individuals may gain certification or continuing-education credits, many of which are available through the American College of Veterinary Pharmacists.
Prescription labels have a lot of details on them, which can make it difficult for patients to find and use important information.
Use of these drugs as medications, though, promising, may be restricted for various reasons to a select few.
Proactive strategies to protect health care data from hackers.
Mobile apps can help consumers acquire medications, but few help with adherence beyond automatic refills or medication synchronization.
Pharmacy personnel can be integrated to optimize antimicrobial use.
These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.